Mast Therapeutics rallies on heart failure data

Mast Therapeutics (MSTX) is up 12% in early action.

The company says MST-188 "demonstrated a statistically significant improvement in numerous parameters of heart function," in a nonclinical heart failure model.

The data collected suggest the treatment may be promising way to improve left ventricular ejection fraction and end-systolic volume.

The company intends to "provide an update on its plans for MST-188 in heart failure later in 2014." (PR)

Comments (1)
  • Andre LaPlume
    , contributor
    Comments (703) | Send Message
    In the headline it should be "heart failure". HEAT failure was a CLSN flashback, and not a pleasant one.
    6 Jan 2014, 08:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs